Damora Therapeutics (DMRA) Cash & Current Investments (2019 - 2026)
Damora Therapeutics (DMRA) posted Cash & Current Investments of $202.4 million for Q1 2026, down 21.44% on a QoQ basis from $257.6 million in Q4 2025, and up 3280.03% year-over-year from $6.0 million in Q1 2025.
Damora Therapeutics (DMRA) Cash & Current Investments (2019 - 2026) Analysis & Trends
Damora Therapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $202.4 million for Q1 2026.
- Quarterly Cash & Current Investments rose 3280.03% year-over-year to $202.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.4 million (up 3280.03% YoY) and the FY2025 annual result came in at $257.6 million, up 1717.45% from the prior year.
- Cash & Current Investments was $202.4 million for Q1 2026 at Damora Therapeutics, down from $257.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $257.6 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
- A 5-year average of $67.2 million and a median of $52.1 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2025 — Cash & Current Investments sank 77.96% — and 2026, when it soared 3280.03%.
- Damora Therapeutics' Cash & Current Investments stood at $60.2 million in 2022, then tumbled by 38.59% to $37.0 million in 2023, then tumbled by 61.67% to $14.2 million in 2024, then soared by 1717.45% to $257.6 million in 2025, then retreated by 21.44% to $202.4 million in 2026.
- Business Quant data shows DMRA's Cash & Current Investments at $202.4 million in Q1 2026, $257.6 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Damora Therapeutics | 1.01 Bn | 807.71 Mn | - | 202.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 202.40 Mn |
| Dec 31, 2025 | 257.62 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 10.21 Mn |
| Mar 31, 2025 | 5.99 Mn |
| Dec 31, 2024 | 14.18 Mn |
| Sep 30, 2024 | 19.70 Mn |
| Jun 30, 2024 | 12.73 Mn |
| Mar 31, 2024 | 27.17 Mn |
| Dec 31, 2023 | 36.98 Mn |
| Sep 30, 2023 | 61.05 Mn |
| Jun 30, 2023 | 52.12 Mn |
| Mar 31, 2023 | 53.25 Mn |
| Dec 31, 2022 | 60.22 Mn |
| Sep 30, 2022 | 101.49 Mn |
| Jun 30, 2022 | 126.89 Mn |
| Mar 31, 2022 | 93.60 Mn |
| Dec 31, 2021 | 100.19 Mn |
| Sep 30, 2021 | 102.14 Mn |
| Jun 30, 2021 | 101.81 Mn |